

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:)	
U.S. Patent No. 5,637,310)	
)	
Randall K. JOHNSON)	Group Art Unit: Unassigned
)	
Reissue Serial No.: Unassigned)	Examiner: Unassigned
)	
Filed: Herewith)	
)	
For: METHOD OF TREATING PROSTATIC)	
ADENOCARCINOMA)	

BOX REISSUE

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

This amendment is being submitted concurrently with a request for reissue of the above-identified patent. Prior to examination of this reissue application, please amend it as follows:

In the Specification:

Col. 1, line 5, after "U.S. Pat. No. 5,496,556" insert -- , which is a continuation of application Ser. No. 544,709, filed June 27, 1990, now U.S. Pat. No. 5,300,294 --.

Remarks

The purpose of this reissue application is to claim priority for this patent ("the '310 patent") back to the original application in the series that led to it. As issued, the '310 patent correctly stated that it is a continuation of application Serial No. 08/170,481, filed December 20,

Reissue Application of
U.S. Patent No. 5,637,310
Atty. Docket No. 14509-C2 RI

1993, now U.S. Patent No. 5,496,556 ("the '556 patent"). However, omitted from that cross-reference was citation of the fact that the '556 patent itself was a continuation of the original application in the series, Serial No. 544,709, filed June 27, 1990, now U.S. Pat. No. 5,300,294 ("the '294 patent"). In this Preliminary Amendment, the specification has been amended to expressly cross-reference the application, Serial No. 544,709, which issued as the '294 patent. There has been no change in the claims from claims 1-2 as issued.

For the foregoing reasons, Patent Owner respectfully submits that claims 1-2 of this application are in condition for allowance. The Examiner is advised that the '310 patent is involved in pending Interference No. 104,646, and that addition of this reissue application to the interference is being sought. Early notification that this reissue application is in condition for allowance is respectfully requested.

If there are any fees due in connection with the filing of this Preliminary Amendment not already accounted for, please charge the fees to our Deposit Account No. 19-2570.

Respectfully Submitted,

September 13, 2001
Date

Wayne J. Dustman
Wayne J. Dustman
Registration No. 33,870
Attorney for GlaxoSmithKline

GlaxoSmithKline
709 Swedeland Road
P.O. Box 1539
King of Prussia, PA 19406-0939